Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
Our study provides clinical evidence that NSCLC patients after osimertinib progression with unknown resistance mechanisms may benefit from immunotherapy + chemotherapy, with higher ORR and longer PFS compared with osimertinib + bevacizumab or chemotherapy groups. Osimertinib + bevacizumab treatment was also an optional option for patients because OS was numerically longer and safer in this group.
Authors
- Yong He (ORCID: https://orcid.org/0000-0002-9404-798X)
- Xin Liao (ORCID: https://orcid.org/0000-0001-8045-3795)
- Pian Liu (ORCID: https://orcid.org/0000-0001-5780-3902)
- Xiong Wan
- Yubo Wang (ORCID: https://orcid.org/0000-0002-1019-5388)
- Jing Li (ORCID: https://orcid.org/0000-0001-7185-145X)
- Tingting He (ORCID: https://orcid.org/0000-0001-7523-6550)
Institutions
- Army Medical University (CN)
- Chongqing University (CN)
- Daping Hospital (CN)
- Jiangjin Central Hospital (CN)
Publication Details
- Journal
- The Clinical Respiratory Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1111/crj.70025
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.09